Evidence supports ribavirin use in Crimean-Congo hemorrhagic fever

International Journal of Infectious Diseases

Volumn 29, Issue , 2014, Pages 296-

  Ergonul, Onder ^a  

^a KOÇ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; ANTIVIRUS AGENT;

CONSENSUS; CRIMEAN CONGO HEMORRHAGIC FEVER; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; FATALITY; HEALTH CARE PERSONNEL; HUMAN; LETTER; NAIRO VIRUS; NEEDLESTICK INJURY; POST EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TURKEY (REPUBLIC); TURKISH CITIZEN; UNSPECIFIED SIDE EFFECT; HEMORRHAGIC FEVER, CRIMEAN;

ANTIVIRAL AGENTS; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; RIBAVIRIN;

EID: 84916879563     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.08.016     Document Type: Letter

References (13)

1. Ceylan B., Calica A., Ak O., Akkoyunlu Y., Turhan V. Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience. Int J Infect Dis 2013, 17:e799-e801.
2. Dokuzoguz B., Celikbas A.K., Gok S.E., Baykam N., Eroglu M.N., Ergonul O. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin Infect Dis 2013, 57:1270-1274.
3. Ozbey S.B., Kader C., Erbay A., Ergonul O. Early use of ribavirin is beneficial in Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2014, 14:300-302.
4. Celikbas A.K., Dokuzoguz B., Baykam N., Gok S.E., Eroglu M.N., Midilli K., et al. Crimean-Congo hemorrhagic fever among health care workers, Turkey. Emerg Infect Dis 2014, 20:477-479.
5. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008, 78:125-131.
6. Ergonul O., Celikbas A., Dokuzoguz B., Eren S., Baykam N., Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004, 39:284-287.
7. Tasdelen Fisgin N., Ergonul O., Doganci L., Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 2009, 28:929-933.
8. Ozkurt Z., Kiki I., Erol S., Erdem F., Yilmaz N., Parlak M., et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006, 52:207-215.
9. Ergonul O. DEBATE (see Elaldi N et al., Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. Journal of Infection 2009; 58: 238-244): biases and misinterpretation in the assessment of the efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever. J Infect 2009; 59:284-6; author reply 286-9.
10. Elaldi N et al., Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. Journal of Infection 2009; 58: 238-244
11. Arda B., Aciduman A., Johnston J.C. A randomised controlled trial of ribavirin in Crimean Congo haemorrhagic fever: ethical considerations. J Med Ethics 2012, 38:117-120.
12. Koksal I., Yilmaz G., Aksoy F., Aydin H., Yavuz I., Iskender S., et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010, 47:65-68.
13. Duygu F., Kaya T., Baysan P. Re-evaluation of 400 Crimean-Congo hemorrhagic fever cases in an endemic area: is ribavirin treatment suitable?. Vector Borne Zoonotic Dis 2012, 12:812-816.